Hemophilia A Clinical Trials

37 recruiting

Hemophilia A Trials at a Glance

52 actively recruiting trials for hemophilia a are listed on ClinicalTrialsFinder across 6 cities in 37 countries. The largest study group is Phase 3 with 11 trials, with the heaviest enrollment activity in Tianjin, Los Angeles, and Beijing. Lead sponsors running hemophilia a studies include Institute of Hematology & Blood Diseases Hospital, China, Hoffmann-La Roche, and Pfizer.

Browse hemophilia a trials by phase

Treatments under study

About Hemophilia A Clinical Trials

Looking for clinical trials for Hemophilia A? There are currently 37 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hemophilia A trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hemophilia A clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 52 trials

Recruiting
Phase 3

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

Hemophilia AHemophilia B
Pfizer173 enrolled17 locationsNCT05568719
Recruiting
Phase 1Phase 2

A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

Hemophilia A
Hoffmann-La Roche5 enrolled2 locationsNCT07226206
Recruiting
Phase 3

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

Hemophilia A
Emory University5 enrolled2 locationsNCT04563520
Recruiting
Phase 1

Lentiviral FVIII Gene Therapy

Hemophilia A
Shenzhen Geno-Immune Medical Institute10 enrolled1 locationNCT03217032
Recruiting
Phase 3

Safety of KN057 Prophylaxis in Patients With Haemophilia A or B

Hemophilia A or B
Suzhou Alphamab Co., Ltd.70 enrolled1 locationNCT07545395
Recruiting

Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders

Cystic FibrosisHuntington DiseaseSickle Cell Disease+12 more
Assistance Publique - Hôpitaux de Paris550 enrolled1 locationNCT06147414
Recruiting

ATHNdataset Registry

ThrombosisSickle Cell DiseaseHemophilia A+6 more
American Thrombosis and Hemostasis Network200,000 enrolled1 locationNCT06820515
Recruiting

A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A

Hemophilia AProphylaxis of BleedingTreatment of Bleeding
Bayer20 enrolled1 locationNCT06222697
Recruiting
Phase 3

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Hemophilia AHemophilia B
Pfizer245 enrolled75 locationsNCT05145127
Recruiting
Phase 3

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

Hemophilia A
Hoffmann-La Roche126 enrolled2 locationsNCT07416526
Recruiting
Phase 3

A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

Hemophilia A
Hoffmann-La Roche360 enrolled3 locationsNCT07416604
Recruiting

Joint Health, Balance and Quality of Life in Adults With Hemophilia A

Hemophilia A
Yuzuncu Yil University36 enrolled1 locationNCT07523399
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Hemophilia A
Hoffmann-La Roche60 enrolled14 locationsNCT05987449
Recruiting
Phase 1

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

Severe Hemophilia A
Pfizer15 enrolled4 locationsNCT06703606
Recruiting
Phase 3

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

Hemophilia AHemophilia B
Pfizer100 enrolled66 locationsNCT05611801
Recruiting
Phase 4

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

Hemophilia A
Swedish Orphan Biovitrum250 enrolled27 locationsNCT06940830
Recruiting
Phase 2Phase 3

Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs

Hemophilia A
Shanghai Xinzhi BioMed Co., Ltd.55 enrolled10 locationsNCT06111638
Recruiting
Phase 1

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)

Healthy ParticipantsHemophilia AHemophilia B+1 more
Equilibra Bioscience LLC31 enrolled10 locationsNCT06349473
Recruiting
Phase 1

Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A

Hemophilia A
Swedish Orphan Biovitrum24 enrolled8 locationsNCT06579144
Recruiting

Hemophilia A Research Program

PregnancyHemophilia APregnancy Complications+10 more
University of Washington500 enrolled1 locationNCT07414511